NICE TA606 lanadelumab cut UK HAE attack frequency from 12 a year to 1.5, an 87% reduction.

Hereditary angioedema is a genetic disorder of the complement and kinin cascade causing recurrent, unpredictable subcutaneous and submucosal swelling episodes, with laryngeal attacks carrying fatal risk if untreated. The UK HAE Alliance estimates 1,500 to 2,000 UK patients, approximately 1 in 32,000 of the population. HAE with C1-inhibitor deficiency, Type 1 or 2, accounts for roughly 85% of cases, with HAE with normal C1-INH, either oestrogen-related or FXII mutation-driven, making up the remaining 15%.

NHS Genomic Medicine Service offers free SERPING1 gene testing as part of the immunodeficiency and angioedema gene panel, driving one of the highest diagnosis rates globally. UK HAE Alliance survey data show mean attack frequency falling from 12 attacks a year before lanadelumab to 1.5 attacks a year after NICE TA606 commissioning, an 87% reduction consistent with the HELP trial, with annual emergency room attendance for laryngeal HAE falling from 45% to under 5%.

One NICE decision cut UK HAE attacks by 87%.

Five questions this report answers:

Q1 - What is the size of the NHS-commissioned HAE prophylaxis population pending berotralstat review?

Q2 - How does NHS GMS SERPING1 cascade testing drive UK HAE diagnosis rates?

Q3 - What has NICE TA606 lanadelumab commissioning changed about UK HAE disease burden?

Q4 - How has NICE TA606 lanadelumab changed UK HAE disease burden under NHS care?

Q5 - How far has laryngeal HAE ER attendance fallen since NICE TA606 commissioning?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HAE #HereditaryAngioedema #NICE #NHS #UKHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/hereditary-angioedema/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/